AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
NCT00343408
Completed
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with standard combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171 when given together with stan... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/03/2023
Locations: Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario +2 locations
Conditions: Colorectal Cancer, Lung Cancer
Register for Updates
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
NCT00820248
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Cross Cancer Institute, Edmonton, Alberta +18 locations
Conditions: Head and Neck Cancer
Register for Updates
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00869752
Completed
RATIONALE: Monoclonal antibodies, such as MK-0646, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of MK-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario +2 locations
Conditions: Lung Cancer
Register for Updates
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
NCT00993655
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube ca... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Mercy-Springfield, Springfield, Missouri +49 locations
Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
NCT01783197
Completed
This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed. Although the number of treatment options for patients with advanced non-small cell lung cancer has increased over the past decade, prognosis remains poor, and there is a need for additional therapeutic options.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: BCCA - Vancouver Cancer Centre, Vancouver, British Columbia +3 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
NCT01846390
Completed
This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type and severity of side effects will result from the combination of these treatments. This research is also being done because it is not clear if the addition of the new drug romidepsin to treatment with GDP can offer better results and longer survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Tom Baker Cancer Centre, Calgary, Alberta +5 locations
Conditions: Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Register for Updates
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT02855944
Completed
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/07/2023
Locations: Rocky Mountain Cancer Center, Denver, Colorado +76 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NCT04163900
Terminated
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: * The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care * The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: Arizona Oncology Associates , PC - HOPE, Tucson, Arizona +124 locations
Conditions: Biliary Tract Cancer
Register for Updates
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
NCT00134030
Completed
This randomized phase III trial is studying combination chemotherapy followed by surgery and two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to compare how well they work in treating patients with osteosarcoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Biological therapies,... Read More
Gender:
ALL
Ages:
Between 5 years and 40 years
Trial Updated:
05/10/2023
Locations: Children's Hospital of Alabama, Birmingham, Alabama +217 locations
Conditions: Localized Osteosarcoma, Metastatic Osteosarcoma
Register for Updates
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
NCT02983045
Completed
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further asses... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2023
Locations: UCSD, Moores Cancer Center, La Jolla, California +57 locations
Conditions: Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Register for Updates
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
NCT02659059
Completed
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Sharp Memorial Hospital, San Diego, California +31 locations
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00492778
Unknown
This randomized phase II trial studies radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with endometrial cancer that has come back. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
03/03/2023
Locations: Sutter Auburn Faith Hospital, Auburn, California +440 locations
Conditions: Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Cancer
Register for Updates